Brem Henry 4

What Happened

• Brem Henry, a director of Galectin Therapeutics, Inc. (GALT), received a grant of 60,000 stock options reported as a derivative acquisition on March 12, 2026. The Form 4 lists the acquisition price as $0.00 (award), indicating an option grant rather than a market purchase or exercise.

Key Details

• Transaction date: March 12, 2026; Form 4 filed March 17, 2026 (appears to miss the 2-business-day Section 16 filing deadline).
• Reported transaction: 60,000 derivative securities (stock options) @ $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnotes: (1) Options issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. (2) Options vest 100% on December 31, 2026.
• No exercise or sale was reported in this filing.

Context

• These are option awards (future rights to buy stock) rather than immediate purchases or sales. They typically serve as compensation and will only dilute outstanding shares if/when exercised. Grants are informative about compensation but are not the same signal as an insider buying stock with personal funds. The filing date suggests the report was filed after the standard 2-business-day window for Section 16 insiders, which may be noted by compliance officers or regulators.